Altimmune, Inc. (ALT)
NASDAQ: ALT · Real-Time Price · USD
6.83
-0.03 (-0.44%)
At close: Jan 21, 2025, 4:00 PM
6.92
+0.09 (1.30%)
After-hours: Jan 21, 2025, 7:42 PM EST
Altimmune Employees
Altimmune had 59 employees as of December 31, 2023. The number of employees increased by 7 or 13.46% compared to the previous year.
Employees
59
Change (1Y)
7
Growth (1Y)
13.46%
Revenue / Employee
$881
Profits / Employee
-$1,754,576
Market Cap
485.78M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
ALT News
- 22 days ago - Altimmune Could Find A Partner For Its Phase 3 Exercise - Seeking Alpha
- 4 weeks ago - Altimmune Added to Nasdaq Biotechnology Index - GlobeNewsWire
- 5 weeks ago - Altimmune 2025: Redefining Obesity And MASH Treatment - Seeking Alpha
- 2 months ago - Altimmune to Participate at Two Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting® 2024 - GlobeNewsWire
- 2 months ago - Altimmune: Pemvidutide As MASH Drug Could Provide Competitive Edge - Seeking Alpha
- 2 months ago - Altimmune's Pemvidutide Gains Momentum: Sizeable TAMs In Obesity And Liver Health - Seeking Alpha
- 2 months ago - Altimmune, Inc. (ALT) Q3 2024 Earnings Call Transcript - Seeking Alpha